The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
Pyrazole derivative as SCD1 inhibitors for the treatment of diabetes
申请人:Novartis AG
公开号:US08314138B2
公开(公告)日:2012-11-20
The present invention provides heterocyclic derivatives of formula I that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
wherein Q is
2-(PYRAZIN-2-YL)-THIAZOLE AND 2-(1H PYRAZOL-3-YL)-THIAZOLE DERIVATIVES AS WELL AS RELATED COMPOUNDS AS STEAROYL-COA DESATURASE (SCD) INHIBITORS FOR THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND OTHER DISORDERS
[EN] The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed. [FR] La présente invention concerne des dérivés hétérocycliques qui modulent l'activité de la stéaroyl-CoA désaturase. L'invention concerne également des procédés d'utilisation de tels dérivés pour moduler l'activité de la stéaroyl-CoA désaturase et des compositions pharmaceutiques comprenant de tels dérivés.